Synthetic Biology · global
Reworking tRNA Ends Opens a Broader Chemical Space for Protein Design
AGENTEX brings modified transfer RNAs and ribosomes into test tubes, establishing a design framework for 34 independently assignable codons. Experiments have demonstrated the incorporation of nonstandard amino acids, but producing a protein containing 34 different amino acids remains some way off.
Giving proteins access to more types of chemical building blocks could allow researchers to design molecular functions rarely found in nature for use in drugs or new materials. However, rewriting the rules of protein production inside living cells often affects the entire machinery of life. A Harvard research team has proposed another route: moving design and testing into test tubes, first teaching the cell’s molecular machinery new rules.
The automated platform, called AGENTEX, was developed by first author Felix Radford, senior author George Church, and colleagues. The study was published in *Nature* on August 26. It uses extracts containing cellular molecular components but no intact living cells, together with modified transfer RNAs (tRNAs) and ribosomes, to test rearranged genetic codes without having to rewrite a living cell’s genome before each test.
The key lies at the end of tRNA. tRNAs deliver amino acids to ribosomes, and mature tRNAs typically end with the three bases CCA, a sequence that also plays a role in ribosome recognition. The researchers found that naturally occurring aminoacyl-tRNA synthetases in Escherichia coli were more tolerant of changes to this end than previously expected: many tRNAs with alternative terminal sequences could still be charged with amino acids. Pairing tRNAs ending in CGA with correspondingly modified ribosomes made it possible to establish a system with less cross-interference with the natural translation machinery.
To determine which designs actually worked, the team developed tSCAN to measure amino acid attachment to tRNAs, followed by tSCAN-M, which combines isotope labeling and mass spectrometry to identify the amino acids they carry. This allows screening to go beyond asking whether a product can be made and also check whether the building blocks are being delivered correctly. According to an announcement from the Wyss Institute, the platform also provides free software for Opentrons laboratory robots to help prepare and test different combinations in batches.
The meaning of “34” requires particular clarification. The study established a design framework for 34 independently assignable codons; encoding the 20 standard amino acids with fewer codons would free up slots for other building blocks. The paper demonstrated the incorporation of nonstandard amino acids and the reassignment of up to three codons. It has not yet produced a single protein containing 34 different amino acids. The value of this work lies in enabling more new rules to be tested systematically.
This also sets clear boundaries for subsequent research: incorporating more nonstandard building blocks into the same product will require further validation of translation efficiency, accuracy, and product purity. Which components would need further adjustment to move the system back into living cells also remains unclear. New drugs and materials are potential applications, while this study provides tools for early design and validation. It has not demonstrated any therapeutic benefit or cost advantage in large-scale production.
The research also involves interests in future commercialization. The Wyss Institute disclosed that Radford and Church are named on related patent applications filed by Harvard, and that Church has related financial interests in GRO Biosciences, enEvolv, and Pearl Bio. As these tools move toward more complex protein designs, the key measures of progress will be how many types of new building blocks can be incorporated reproducibly and whether the intended molecules can be produced consistently.